Our goal at MultiplexDX is to eliminate cancer misdiagnosis by launching 98% accurate, quantitative and accessible diagnostic tests

MultiplexDX is one of the most innovative biotech corporations, created to bring revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both  U.S. and European markets. The U.S. site is located in close proximity to the National Institutes of Health as well as the Food and Drug Administration. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).